A phase 1 study of gamma retrovirally modified T cells to treat relapsed leukaemia has recently been initiated to investigate the safety and efficacy of a recombinant αβ TCR specific for HLA-A2/WT1 peptide antigen (ClinicalTrials.gov; NCT01621724). Here, WT1 is linked to leukemia.